CLINICAL STUDIES

DELIVER

An International, Double-blind, Randomized, Placebo-Controlled Phase III Study to Evaluate the Effect of Dapagliflozin on Reducing CV Death or Worsening Heart Failure in Patients with Heart Failure with Preserved Ejection Fraction (HFpEF)

Study Phase:

Phase 3

Criteria:

  • Male or Female 40 years or older
  • Symptomatic heart failure (NYHA class II-IV)
  • Left Ventricular Ejection Fraction (LVEF) >40%
Register